Clinical Trial Update: Safety and Immunogenicity Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine. [Phase 3]

View source ↗

Summary

Phase 3 safety and immunogenicity results for a booster dose of GSK's 10-valent pneumococcal conjugate vaccine have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections
• Streptococcal Infections

Drugs mentioned

• 10-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine (10-valent))

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Streptococcal | Phase 3 | Status: COMPLETED | Results posted: 2018-11-26